LYEL Lyell Immunopharma, Inc.
USHealthcareAs of 2026-10-08
Why LYEL matters now
Lyell Immunopharma, Inc. (LYEL) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.79 with +2.69% on the session and $215.4M in market capitalization; recent performance reads 1-month -21.02% and YTD -58.61%.
The latest financial table shown here is Q1 2026, with revenue of $2.0K, net income of $-24.2M, and EPS of $-1.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -45.2%.
The latest indexable market news headline is "Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $47.00; recent insider activity includes Innovative Cellular Therapeutics Holdings Ltd filing J-Other. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.02
P/S
9589.56
EV/EBITDA
-1.07
DCF Value
$0.35
FCF Yield
-45.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-7422.6%
Operating Margin
-618909.7%
Net Margin
-794858.1%
ROE
-85.7%
ROA
-70.3%
ROIC
-59.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.0K | $-24.2M | $-1.10 |
| Q4 2025 | $6.0K | $-140.7M | $-6.62 |
| FY 2025 | $36.0K | $-274.4M | $-16.06 |
| Q3 2025 | $15.0K | $-38.8M | $-2.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$47.00
Target (Median)
$47.00
Target Range
$45.00 - $49.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.09
Lyell Immunopharma, Inc. (LYEL) is a firm specializing in T cell reprogramming, dedicated to crafting T cell therapies for individuals battling solid tumors. The company's therapeutic innovation relies on advanced technology platforms: Gen-R, an ex vivo genetic reprogramming technique engineered to counteract T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming method designed to cultivate T cells with sustained stem-like properties. Its development pipeline features notable candidates such as LYL797, a T cell product aimed at non-small cell lung cancer and triple-negative breast cancers; LYL845, intended for a broad range of solid tumors; and NY-ESO-1, focusing on synovial sarcoma and other specific solid tumor conditions. Additionally, Lyell holds a research and development collaboration and licensing agreement with GlaxoSmithKline for the NY-ESO-1 initiative. Founded in 2018, the company's main office is situated in South San Francisco, California.